GSE34228   Details

GSE Accession GSE34228
Title Time-course gene expression profiles of gefitinib-sensitive or -resistant lung adenocarcinoma cells stimulated with EGF, in the presence or absence of gefitinib, EGF receptor tyrosine kinase-specific inhibitor
Submission Date 2011-12-07
Last Update Date 2014-01-02
Pubmed ID 26268703
Experiment Type Expression profiling by array
Contributor Noriko,,Gotoh
Contact Name Noriko Gotoh
Contact E-mail ngotoh@ims.u-tokyo.ac.jp
Organization Name The University of Tokyo
Country Japan
Organism Homo sapiens
Organism ID
Organism Synonym man;human
Summary Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), induces substantial clinical responses for non-small cell lung cancer (NSCLC) cells harboring EGFR activating mutations, but most of them invariably develop resistance. By generating a gefitinib resistance (PC9GR) from a human NSCLC-derived drug sensitive cell line (PC9), we studied differences of transcription dynamics between them by the aid of a computational decoupling of hidden regulatory signals from time course gene expression profiles. Given a collection of transcription factors (TFs) and their regulatory targets, the method captured temporally-synchronized shifts in evolving expression of target genes sharing each TF regulatory unit, and drew underlying regulatory signals. The analysis identified sterol regulatory element binding protein 1 (SREBP-1) as a key regulatory agent that facilitates the maintenance of drug tolerance, involving transcription controls of a G1-specific cyclin dependent kinase inhibitor whose expression was specifically elevated in PC9, but in turn, reduced in PC9GR
Overall Design Gefitinib-resistance cell line (PC9GR) was established derived from lung adenocarcinoma cell line PC9. PC9 cells and PC9GR cells were treated with the four different conditions, control (No treatment), EGF-treatment, gefitinib-treatment, and both gefitinib and EGF-treatment. In each condition, the gene expression was measured at 26 time points during 24 hrs.
Platform ID
Timepoint Count 26
Timepoints gse: [Timepoints, 26]
Disease non-small cell lung carcinoma;
lung adenocarcinoma;
lung cancer;
adenocarcinoma;
carcinoma;
lung carcinoma;
thrombocytopenia-absent radius syndrome;
congenital disorder;
thrombocytopenia
Disease ID 3908;
3910;
1324;
299;
305;
3905;
14699;
759;
1588